Clinical Approach to Substance Use and Detoxification

Universal, non-stigmatizing screening

The identification of substance use patterns in adolescent pregnant women should be based on systematic and confidential protocols to overcome fears of legal sanctions or loss of custody.

Screening should not be based on subjective profiles but should be applied universally from the first prenatal visit using validated questionnaires such as the CRAFFT instrument or the 4Ps test.

Laboratory tests for toxic substances in urine always require prior informed consent and should be viewed as diagnostic tools intended to guide medical care, never as punitive control mechanisms.

The consultation should provide a safe environment where assertive communication and motivational interviewing help the patient recognize risks without blame, thereby minimizing dropout from clinical follow-up.

Harm Reduction and Detoxification Treatment

The management of substance dependence in adolescent pregnant women prioritizes specialized psychotherapeutic interventions and harm reduction programs that minimize the toxic impact on the fetus.

In cases of opioid addiction, detoxification or abrupt withdrawal is formally contraindicated due to the high risk of triggering acute fetal distress, myometrial hyperactivity, and pregnancy loss; the care protocol recommends maintenance treatment with long-acting opioid agonists (methadone or buprenorphine) under strict medical supervision.

The detoxification plan should involve toxicologists, mental health specialists, and social workers, ensuring access to community support networks and assessing associated psychiatric comorbidities to ensure the patient’s stability.